НПВП-гастропатия — скрытая угроза при лечении боли

Abstract

INTRODUCTION. NSAID gastropathy is one of the possible negative consequences of taking non-steroidal anti-inflammatory drugs (NSAIDs), characterized by pathological changes in the gastrointestinal tract. The disease is often asymptomatic, which is the reason for its low detectability during outpatient appointments. The risks of developing serious complications from the gastrointestinal tract (ulcers, bleeding, perforations) increase 3-fold already in the first days of NSAID use. Even a short course of NSAID therapy lasting 3–5 days carries a risk of gastrointestinal complications similar to that of long-term treatment. As a consequence, prevention strategies should be implemented regardless of the duration of therapy, especially in patients with more than one risk factor. CONCLUSION. The risks of complications when taking this group of drugs can be significantly reduced by drug prophylaxis in patients with risk factors for the development of NSAID-gastropathy. Proton pump inhibitors are the main means of preventing possible adverse drug reactions of NSAIDs from the upper gastrointestinal tract. Physicians should consider the need for prophylactic use of proton pump inhibitors throughout the duration of NSAID use. Omez® 20 mg has indications for both prevention and treatment of NSAID-associated gastropathy and can be recommended to such patients from the first day of NSAID intake regardless of the course duration of NSAID intake. KEYWORDS: pain, gastroenterology, geriatrics, gastrointestinal bleeding, gastrointestinal tract, proton pump inhibitors, neurology, adverse events, nonsteroidal anti-inflammatory drugs, NSAIDs, NSAID-associated complications, NSAID gastropathies, general surgery, prevention, therapy, risk factor, chronic pain